Less post-covid symptoms among remdesivir-treated patients

SESSION TITLE: Chest Infections Posters 1 SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/10/2023 12:00 pm - 12:45 pm PURPOSE: The outbreak of COVID-19 (coronavirus disease-19) has resulted in the hospitalization of numerous patients around the world. A large proportion of patients reported post-COVID symptoms after the recovery of COVID-19. The most common post-COVID symptom is fatigue, however it can affect any organ systems, like respiratory tract or neuro-psychical system. Remdesivir has been widely used as a treatment option for COVID-19. The objective of this study was to evaluate the efficacy of remdesivir in post-COVID symptoms in patients who were previously hospitalized. METHODS: Our retrospective study enrolled in the post-COVID care of the Department of Pulmonology at Semmelweis University between 01/02/2021-30/06/2022. Out of 386 patients 267 were previously hospitalized. They were categorized based on whether they received standard of care (SOC; N=99) or additional remdesivir (RDV; N=168) treatment. Data of patient characteristics, symptoms during and after COVID-19 and therapy during infection were collected. Additionally, detailed lung function test, 6-minute walk test (6MWT) and visual analogue scale (VAS) were performed in the post-COVID care. RESULTS: Age (group SOC: 44.3±14.0; group RDV: 47.5±15.5 years) and BMI (body mass index; 26.7±5.9 vs. 27.8±6.5 kg/m2) were similar in both groups, as well as sex distribution (female 57.6 vs. 49.4%). Length of hospital stay were 18.8±15.7 vs. 14.4±12.8 days in groups respectively (p=0.01). RDV treated patients applied earlier at post-COVID care (average 125.2±133.2 vs 78.2±82.2 days, p=0.002). Patients treated with RDV had greater lung involvement on CT-scans and more patients required oxygen supplementation at initial infection. Main symptoms by post-COVID patients were respiratory (43.4 vs 28.0%, p<0.01), fatigue (58.6 vs 28.6%, p<0.01) and sleep disorders (40.4 vs. 13.1%, p<0.01), however all initial COVID symptoms were similar. Although there was no significant difference in functionality (lung function and 6MWT parameters) between the groups, however RDV-treated group reported significantly better patient-reported outcomes by VAS (71.1±19.1 vs. 75.7±16.0; p=0.05). CONCLUSIONS: Results showed that patients treated with RDV spent less time in hospital and also attended post-COVID care earlier than those treated with SOC. Patients on SOC reported significantly more symptoms at the post-COVID care. Remdesivir may reduce the development of post-COVID symptoms and could improve patient-reported outcomes. CLINICAL IMPLICATIONS: Patients who received remdesivir during COVID19 also have benefit in the long term. DISCLOSURES: No relevant relationships by Eniko Barczi No relevant relationships by Dorottya Fesu No relevant relationships by Gabor Horvath No relevant relationships by Veronika Müller No relevant relationships by Alexandra Nagy MD Consultant relationship with Chiesi Hungary kft. Please note: 2022.10.20- Added 03/31/2023 by Lőrinc Polivka, source=Web Response, value=Consulting fee